Background: The transformation of epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) into small cell cancer (SCLC) accounts for 3–14% the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research explore dynamic expression EGFR-mutant proteins and genomic evolution in transformed SCLC/neuroendocrine carcinoma (NEC).

rho-kinase is an effector molecule of rhoa, a monomeric gtp-binding protein, and causes ca2+ sensitization through inactivation of myosin phosphatase. the major physiological functions of rho/rho-kinase cascade include contraction, proliferation and migration in cells.there are some excellent reviews about rho/rho-kinase signal pathway, most of which focus on the specific proteins of the pathwa...

Novel inhibitors that target the Eph family of transmembrane tyrosine kinase receptors have been optimized and characterized. Some compounds show remarkable receptor selectivity affinity for inhibit growth colon cancer cells where these are expressed active. More information can be found in Research Article by G. Tosato, H. Schwalbe co-workers (DOI: 10.1002/chem.202203967).

Oesophageal and oesophagogastric junction cancers represent a significant burden to public health. Clinical practice guidelines recommend treatment based on cellular molecular targets from tissue obtained before initiating therapy, including human epidermal growth factor receptor, microsatellite instability, mismatch repair, programmed death-ligand 1 neurotrophic receptor tyrosine kinase gene f...

Background: Lazertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to overcome EGFR T790M mutation. Currently, lazertinib approved for usage in the acquired mutation population based on promising clinical and safety profiles. In this study, we evaluated outcomes of mutated non-small cell lung cancer (NSCLC) patients real-world setting.

results isotype of 1f1 clone was determined to be igg1, which reacted with native protein in the western blot experiment and stained 20% of the membrane of neoplastic cells overexpressing her2 with 3+ grade. however, 3l5 clone showed a low reaction (10%) with native her2 in immunohistochemistry. conclusions the results of both western blotting and immunohistochemistry showed that native her2 ca...

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with metastatic non-small cell lung cancers (NSCLC) harbouring epidermal growth factor receptor mutations (EGFRm). However, role TKIs is not established in management stage III EGFRm disease. We describe real-world practice testing and use NSCLC KINDLE study, a multicentre, multi-country observational non-interventional stu...

Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to ...

Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors (TKI) have transformed traditional cancer treatment and brought good news to patients with non-small cell lung cancer. However, drug resistance problems arise one after another. Based on further exploration of the mechanism EGFR corresponding therapeutic strategies, author reviewed relevant literature, classified summarized it,...

introduction: tyrosine kinase inhibitors (tkis) were the first drugs to use an intracellular signaling molecule as a therapeutic target. unresponsiveness to tkis limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (hsct) the only option leading to molecular remission. objectives: to characterize cml patients unresponsive to first- and/or second-generation tki t...